Alpha Mark Advisors, LLC United Therapeutics Corp Transaction History

Alpha Mark Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 07, 2020	SELL	$78.31 - $95.34 $2.46 Million - $2.99 Million	-31,391 Closed	0 $0
Q3 2019 Nov 01, 2019	SELL	$74.85 - $85.99 $68,712 - $78,938	-918 Reduced 2.84%	31,391 $2.5 Million
Q2 2019 Aug 02, 2019	SELL	$76.06 - $120.81 $103,517 - $164,422	-1,361 Reduced 4.04%	32,309 $2.52 Million
Q1 2019 May 09, 2019	SELL	$107.15 - $126.84 $115,400 - $136,606	-1,077 Reduced 3.1%	33,670 $3.95 Million
Q4 2018 Feb 06, 2019	SELL	$101.4 - $128.73 $277,531 - $352,334	-2,737 Reduced 7.3%	34,747 $3.78 Million
Q3 2018 Nov 05, 2018	SELL	$113.81 - $129.46 $23,444 - $26,668	-206 Reduced 0.55%	37,484 $4.79 Million
Q2 2018 Aug 03, 2018	BUY	$101.14 - $118.31 $84,350 - $98,670	834 Added 2.26%	37,690 $4.27 Million
Q1 2018 May 09, 2018	BUY	$107.21 - $151.94 $3.95 Million - $5.59 Million	36,806 Added 73612.0%	36,856 $4.14 Million
Q3 2017 Nov 02, 2017	BUY	$114.6 - $136.81 $5,730 - $6,840	50	50 $6,000

672

42.4M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Mark Advisors, LLC with notifications on news.